New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
05:42 EDTSNY, AZN, JNJ, ILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
News For ILMN;AZN;SNY;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
09:27 EDTILMNLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools and Diagnostics Dan Leonard, along with Dr. Paul Robson and Dr. Peter Kuhn, discuss the demand for Fluidigm's single cell prep products, including the impact to Biomark and the utility of CyTOF on an Analyst/Industry conference call to be held on July 1 at 2 pm.
09:21 EDTILMNBioMed Realty leases build-to-suit laboratory in Cambridge to Illumina
BioMed Realty (BMR) announced that Illumina ILMN) has signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. BioMed Realty acquired the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty's Granta Park campus in Cambridge, England.
June 24, 2015
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
June 18, 2015
07:36 EDTAZNReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
June 17, 2015
07:51 EDTILMNNIH draft FY16 funding budget better than expected at BofA/Merrill
Last night, the House Appropriations Labor/Health and Human Services Subcommittee released its draft FY16 funding budget. The bill proposed a FY16 funding increase of 3% for the National Institute of Health, versus BofA/Merrill's forecast for a 1% increase. The firm said the proposed boost in funding would be a positive for the Life Sciences & Tools sector, especially iIllumina (ILMN) and Thermo Fisher (TMO) which have the most exposure.
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
June 16, 2015
14:23 EDTAZNReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptos’ pipeline, and maintains an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use